About Barry Shea, MD

Dr. Shea received his undergraduate degree in chemistry from Dartmouth College and his medical degree from Tufts University School of Medicine.  He completed his internal medicine residency at New York-Presbyterian Hospital / Weill Cornell Medical Center and his pulmonary and critical care medicine fellowship at the Harvard Combined Program.  He then completed a postdoctoral fellowship studying the biology of lung fibrosis before becoming a faculty member in the MGH Pulmonary and Critical Care Medicine Division.  Dr. Shea then joined the faculty at Brown University and Rhode Island Hospital (RIH), where he established and led the Brown-RIH Interstitial Lung Disease (ILD) Program, before returning to MGH in 2021.  Dr. Shea’s career has been focused on caring for individuals afflicted with ILDs and conducting basic, clinical, and translational research in the field of pulmonary fibrosis.  He has received NIH funding for his research and has served as site principal investigator for numerous clinical trials in idiopathic pulmonary fibrosis (IPF).

Departments, Centers, & Programs:

Clinical Interests:



Mass General Pulmonary & Critical Care
55 Fruit St.
Boston, MA 02114
Phone: 617-726-1721

Mass General Brigham Healthcare Center
52 Second Ave.
Waltham, MA 02451
Phone: 617-726-1721

Medical Education

  • MD, Tufts University School of Medicine
  • Residency, NewYork-Presbyterian/ Weill Cornell Medical Center
  • Fellowship, Cornell University College of Medicine
  • Fellowship, Harvard (MGH, BWH, BIDMC)
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Critical Care Medicine, American Board of Internal Medicine
  • Pulmonary Disease, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Shea?s research focus is exploring the mechanisms that lead to lung fibrosis and exploring new treatments for this disease process. His research has included basic science, translational, and clinical investigations, and he has received NIH funding for his work. He is currently exploring the use of a novel molecular imaging technique to assess the extent of ongoing lung injury in pulmonary fibrosis, and he is an investigator for several industry-sponsored clinical trials in idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.

Reviews: Comments and Ratings